Indeed, our investigation revealed that the administration of olaparib resulted in a reduction in autophagy in NLRP4-knockdown pancreatic cancer cells, which was correlated with an increased sensitivity to olaparib. The gene discussed is NLRP4; the disease is pancreatic neoplasm.